Posted by Michael Wonder on 31 Oct 2017
Institute for Clinical and Economic Review announces new 13.9 million dollar grant from the Laura and John Arnold Foundation
31 October 2017 - Expanded funding enables ICER value assessments for all newly approved medicines in the US.
The Institute for Clinical and Economic Review (ICER) today announced a three-year, $13.9 million grant from the Laura and John Arnold Foundation (LJAF). The funding will support ICER’s ongoing efforts to transform the way all new prescription drugs are evaluated and priced and will help advance the organisation’s mission to ensure sustainable access to high-value care for all patients.
The new grant is LJAF’s latest investment in ICER, following a two-year, $5.2 million award made to the group in 2015 in support of its efforts to assess new drugs with the potential to significantly affect patient care and health system budgets. Since that time, ICER has produced reports evaluating drugs intended to treat high cholesterol, non-small cell lung cancer, multiple sclerosis, atopic dermatitis, and other conditions.
